Home › Funds › NEXTBio Capital Management LP › LBRX
NEXTBio Capital Management LP position in LBRX
LB PHARMACEUTICALS INC · Health Care
NEXTBio Capital Management LP reported holding 69,549 shares of LBRX (LB PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$2.7M, representing 1.16% of its reported portfolio and ranking #21 among its reported holdings. NEXTBio Capital Management LP has disclosed LBRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's LBRX position evolved
NEXTBio Capital Management LP first disclosed a stake in LBRX in Q2 2026 at 68,249 shares (US$2.2M). The position peaked in Q3 2026 at 69,549 shares, worth US$2.7M. Across 2 filings, NEXTBio Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 69,549 shares valued at US$2.7M — an increase of 1,300 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 68.25K | $2.22M | New |
| Q3 2026 | 69.55K | $2.67M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LBRX and 13F data
LBRX (LB PHARMACEUTICALS INC) is a Health Care company. 106 other funds we track also report a position in LBRX — the largest reported positions include Deep Track Capital, LP (US$108.8M), RA CAPITAL MANAGEMENT, L.P. (US$71.7M), Trails Edge Capital Partners, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LBRX
- Deep Track Capital, LP 3.35M sh · $108.82M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.21M sh · $71.68M · Q2 2026
- Trails Edge Capital Partners, LP 1.52M sh · $49.43M · Q2 2026
- Commodore Capital LP 1.50M sh · $48.68M · Q2 2026
- TCG Crossover Management, LLC 1.45M sh · $46.97M · Q2 2026
- Caligan Partners LP 1.44M sh · $46.67M · Q2 2026
- Spruce Street Capital LP 1.38M sh · $44.66M · Q2 2026
- Nantahala Capital Management, LLC 1.05M sh · $34.17M · Q2 2026
- Vivo Capital, LLC 800.00K sh · $30.70M · Q3 2026
- Nan Fung Group Holdings Ltd 630.66K sh · $20.47M · Q2 2026
- Logos Global Management LP 585.00K sh · $18.99M · Q2 2026
- GREAT POINT PARTNERS LLC 317.22K sh · $10.30M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held LBRX?
NEXTBio Capital Management LP has disclosed LBRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is NEXTBio Capital Management LP's current position in LBRX?
As of Q3 2026, NEXTBio Capital Management LP holds 69.55K shares of LBRX (LB PHARMACEUTICALS INC), valued at $2.67M, representing 1.16% of its reported portfolio and ranking #21.
Has NEXTBio Capital Management LP been buying or selling LBRX?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP increased its position in LBRX. The position peaked in Q3 2026 at 69.55K shares.
Which other funds hold LBRX?
Other major institutional holders of LBRX include Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., Trails Edge Capital Partners, LP, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.